184 related articles for article (PubMed ID: 23686402)
21. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Jackisch C; von Minckwitz G; Eidtmann H; Costa SD; Raab G; Blohmer JU; Schütte M; Gerber B; Merkle E; Gademann G; Lampe D; Hilfrich J; Tulusan AH; Caputo A; Kaufmann M
Clin Breast Cancer; 2002 Oct; 3(4):276-80. PubMed ID: 12425756
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Rischin D; Ackland SP; Smith J; Garg MB; Clarke S; Millward MJ; Toner GC; Zalcberg J
Ann Oncol; 2002 Nov; 13(11):1810-8. PubMed ID: 12419756
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Alexopoulos A; Kouroussis C; Malamos N; Kakolyris S; Kalbakis K; Kosmas C; Mavroudis D; Agelaki S; Vlachonicolis J; Sarra E; Rigatos G; Georgoulias V
Ann Oncol; 2001 Jun; 12(6):793-8. PubMed ID: 11484954
[TBL] [Abstract][Full Text] [Related]
24. A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
Mitchell PL; Basser R; Chipman M; Grigg A; Cebon J; Davis ID; Zalcberg J; Ng S; Appia F; Green M
Ann Oncol; 2003 May; 14(5):788-94. PubMed ID: 12702535
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Sparano JA; O'Neill A; Schaefer PL; Falkson CI; Wood WC
J Clin Oncol; 2000 Jun; 18(12):2369-77. PubMed ID: 10856096
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
27. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
28. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
[TBL] [Abstract][Full Text] [Related]
30. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Doctors' and Breast Cancer Patients' Perceptions of Docetaxel, Epirubicin, and Cyclophosphamide (TEC) Toxicity.
Bayo J; Prieto B; Rivera F
Breast J; 2016 May; 22(3):293-302. PubMed ID: 26864346
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
33. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study.
Antolín S; Mel R; Ramos M; García-Palomo A; Almanza C; de Paz L; Calvo L; Alvarez E; González A; García-Mata J
Clin Transl Oncol; 2011 Sep; 13(9):686-91. PubMed ID: 21865141
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
[TBL] [Abstract][Full Text] [Related]
35. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Misset JL; Dieras V; Gruia G; Bourgeois H; Cvitkovic E; Kalla S; Bozec L; Beuzeboc P; Jasmin C; Aussel JP; Riva A; Azli N; Pouillart P
Ann Oncol; 1999 May; 10(5):553-60. PubMed ID: 10416005
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
37. [Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin].
Liutkauskiene S; Sveikata A; Juozaityte E; Characiejus D; Juodzbaliene E; Kregzdyte R; Fokas V
Medicina (Kaunas); 2009; 45(8):600-6. PubMed ID: 19773618
[TBL] [Abstract][Full Text] [Related]
38. Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.
Alba E; Ribelles N; Antón A; Pérez-Carrión R; López-Vega JM; Llanos M; Pelegri A; Florián J; Menéndez M; Godes MJ;
Breast Cancer Res Treat; 2003 Jan; 77(1):1-8. PubMed ID: 12602899
[TBL] [Abstract][Full Text] [Related]
39. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):204-10. PubMed ID: 21358208
[TBL] [Abstract][Full Text] [Related]
40. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
